University of California at San Francisio
Welcome,         Profile    Billing    Logout  
 19 Trials 
27 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aggarwal, Rahul
RENAVIV, NCT03592472 / 2018-001495-38: A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Recruiting
3
413
Europe, US, RoW
Pazopanib, Votrient®, Abexinostat, PCI-24781, Placebo
Xynomic Pharmaceuticals, Inc.
Renal Cell Carcinoma
12/24
06/25
PRESTO, NCT03009981: A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Active, not recruiting
3
504
US
Apalutamide, Erleada, LHRH Analogue, Degarelix (Firmagon), Leuprolide (Lupron) and Bicalutamide, Abiraterone Acetate, Zytiga, Prednisone, Deltasone
Alliance Foundation Trials, LLC., Janssen Research & Development, LLC
Prostate Cancer
07/25
01/26
PILLAR, NCT03503344: Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer

Active, not recruiting
2
26
US
Apalutamide, ARN 509, JNJ 56021927, Stereotactic Body Radiation Therapy, SABR, SBRT, Stereotactic Ablative Body Radiation Therapy
University of California, San Francisco, Janssen Pharmaceuticals
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
06/25
01/27
SYNERGY-201, NCT06228053: Study of SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

Recruiting
2
53
US
SX-682, Enzalutamide, Xtandi
Syntrix Biosystems, Inc., National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer
06/26
06/28
NCT04926181: Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Active, not recruiting
2
2
US
Apalutamide, Erleada, Androgen Receptor Inhibitorsv(ARI), Apalutamide Oral Tablet, Cetrelimab, JNJ-63723283, Anti-PD-1 antibody cetrelimab (JNJ-63723283), CET
Rahul Aggarwal, Janssen Scientific Affairs, LLC
Small Cell Neuroendocrine Carcinoma, Prostate Cancer, Small Cell Carcinoma
03/24
02/25
NCI-2018-01648, NCT03682289: Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Recruiting
2
89
US
Ceralasertib, AZD-6738, AZD6738, ATR Kinase Inhibitor AZD6738, Olaparib, AZD2281, KU-0059436, Lynparza, poly adenosine diphosphate-ribose polymerase (PARP) inhibitor AZD2281, Durvalumab, Imfimzi, MEDI4736, MEDI-4736
Rahul Aggarwal, AstraZeneca
Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
09/27
09/27
NCT04471974: ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
54
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Enzalutamide, ASP9785, MDV3100, Xtandi, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Rahul Aggarwal, Zenith Epigenetics, Merck Sharp & Dohme LLC, U.S. Army Medical Research and Development Command
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
04/27
04/27
NCT05766371: Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Recruiting
2
48
US
Pembrolizumab, Keytruda, 177Lu-PSMA-617, Lutetium-177-PSMA-617, (177Lu)-PSMA-617
University of California, San Francisco, Merck Sharp & Dohme LLC, Prostate Cancer Foundation
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
05/27
05/31
NCT05011188: FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Recruiting
1/2
36
US
FOR46, Antibody-Drug Conjugate (ADC), anti-CD46 antibody conjugate, Enzalutamide, XTANDI, Pegfilgrastim, G-CSF, Blood Samples, Blood Specimen, Biospecimen
Rahul Aggarwal, Fortis Therapeutics, Inc., FibroGen
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
03/27
03/27
NCT03822871: A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

Completed
1
17
US
CTT1403, CTT1057, 68Ga-PSMA-11
Cancer Targeted Technology, University of California, San Francisco, National Cancer Institute (NCI)
Prostate Cancer
10/22
02/23
NCT03590054: Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

Checkmark Interim data in combination with abexinostat for multiple solid tumors
Aug 2019 - Aug 2019: Interim data in combination with abexinostat for multiple solid tumors
Completed
1
35
US
Abexinostat, PCI-24781, Pembrolizumab, Keytruda
Rahul Aggarwal, Xynomic Pharmaceuticals, Inc.
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
11/23
11/23
CP-MGC018-02, NCT05293496: A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Active, not recruiting
1
278
US
vobramitamab duocarmazine, MGC018, lorigerlimab, MGD019
MacroGenics
Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
04/25
06/25
NCT06014658: Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors

Recruiting
1
90
US
Antibody-Drug Conjugate
MBrace Therapeutics
Cancer
07/25
11/25
NCI-2018-02052, NCT02735252: PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

Active, not recruiting
N/A
156
US
Systemic therapy, StrataNGS
University of California, San Francisco, Prostate Cancer Foundation, Strata Oncology
Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
03/27
03/27
Seja, Elizabeth
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
DAR-UM-2, NCT05987332: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Recruiting
2/3
420
Europe, Canada, US, RoW
IDE196, Darovasertib, Crizotinib, XALKORI, Pembrolizumab, Keytruda, Ipilimumab, Yervoy, Nivolumab, Opdivo, Dacarbazine, DTIC-Dome
IDEAYA Biosciences
Metastatic Uveal Melanoma
01/27
01/28
IDE196-009, NCT05907954: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Recruiting
2
82
Europe, Canada, US, RoW
Darovasertib, IDE196, LXS196
IDEAYA Biosciences
Uveal Melanoma
01/26
01/29
H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting
1/2
200
Europe, US
HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Hookipa Biotech GmbH, Hookipa Biotech
HPV-Related Squamous Cell Carcinoma
06/25
06/26
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
02/26
02/26
OPAL-1, NCT05970497: A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Recruiting
1/2
240
US
KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)
Krystal Biotech, Inc.
Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma
07/27
07/27
Lam, Phu
NCT05746208: Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Recruiting
2
29
US
Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Hyperpolarized 13C-Pyruvate, HP 13C
University of California, San Francisco, Merck Sharp & Dohme LLC
Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
07/27
10/27
NCT04418167: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Suspended
1
71
US
JSI-1187, Dabrafenib, TAFINLAR
JS InnoPharm, LLC
Solid Tumors
06/24
12/24
KTX-MMSET-001, NCT05651932: A Study of an MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

Recruiting
1
125
Europe, Canada, US
Cohort A1 & A2, KTX-1001, Dexamethasone, Cohort C1 & C2, Carfilzomib, Cohort D, Pomalidomide
K36 Therapeutics, Inc.
Multiple Myeloma, Myeloma, Myeloma Multiple
12/25
06/26
NCT02332850: Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
83
Canada, US
Isatuximab, SAR 650984, Carfilzomib, Kyprolis, PR-171, Dexamethasone, Orgadrone, Spersadex, Visumetazone
Thomas Martin, MD, Amgen, Sanofi
Multiple Myeloma
12/24
12/24
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
NCT06014658: Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors

Recruiting
1
90
US
Antibody-Drug Conjugate
MBrace Therapeutics
Cancer
07/25
11/25
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Active, not recruiting
1
272
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27

Download Options